Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E2027 MAD Study in Healthy Subjects
NCT02873156Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2016
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) comparing E2027 with Placebo (2 arms). Primary endpoints: Maximum drug concentration at Day 14, Mean predose drug concentration at Day 14 and 10 more. Started Aug 2016; status: completed.
02
Drugs
Irsenontrine
03
Conditions
dementia with Lewy bodies (DLB)Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02873156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02873156.